PT - JOURNAL ARTICLE AU - Singla, Suhas AU - Batra, Sandeep AU - Dougall, Pankaj AU - Dayal, Nitin AU - Naithani, Rahul TI - Prospective Assessment of Bone Marrow Involvement with Positron Emission Tomography vs Bone Marrow Biopsy in Patients with Lymphoma AID - 10.1101/2023.03.21.23287535 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.21.23287535 4099 - http://medrxiv.org/content/early/2023/03/21/2023.03.21.23287535.short 4100 - http://medrxiv.org/content/early/2023/03/21/2023.03.21.23287535.full AB - Background Bone marrow involvement (BM involvement) in lymphoma is a known adverse prognostic factor. Bone marrow biopsy (BMB) is the gold standard for detection of bone marrow involvement but is invasive modality. Positron Emission Tomography with Computed Tomography (PET-CT) scan has the ability to assess bone marrow involvement. We aimed to assess the concordance of PET-CT for BM involvement with BMB.Methods 75 consecutive newly diagnosed cases of lymphoma were enrolled and were assessed for BM involvement with PET-CT and BMB.Results Of 75 patients, eighteen patients (24%) had BM involvement, with 19% (n=14) detected with BMB, and 13 (17%) with FDG 18 PET CT. There was a concordance rate of 88% amongst PET-CT and BMB. It was 92% in Hodgkin’s lymphoma (HL), 71.4% in non-Hodgkin’s lymphoma (NHL), and 91% and 70% in high-grade (HG) and low-grade (LG) NHL, respectively. Sensitivity, specificity, PPV, NPV, and accuracy of PET-CT for study population were 69.23%, 93.44%, 69.23%, 93.44%, and 89.19 % respectively. In patients with NHL sensitivity, specificity, NPV, PPV, and accuracy of PET-CT were 54.55%, 94.23%, 66.67%, 90.74%, and 87.30%, respectively; whereas in HL group these were 100%, 88.89%, 75%, 100%, and 91.67%, respectively.Conclusions PET-CT has got a high concordance with bone marrow biopsy in detecting bone marrow involvement with high specificity, NPV and accuracy. A high sensitivity, specificity, NPV and accuracy for detecting bone marrow involvement in patients with HL, aggressive B cell NHL, and T cell NHL was observed but the same parameters were not at par in patient with indolent (low-grade) NHL.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Max Superspeciality Hospital, Saket gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript